主管单位:中华人民共和国
国家卫生健康委员会
主办单位:
总编辑:杨秋
编辑部主任:吴翔宇
邮发代号:80-528
定价:28.00元
全年:336.00元
Email:zgyy8888@163.com
电话(传真):010-64428528;
010-64456116(总编室)
英文作者:Liu Lijun Liao Fujun Li Junqing Li Jieqi
英文单位:Department of Cardiovascular Medicine the Affiliated Hospital of Guizhou Medical University Guiyang 550000 China
英文关键词:Lipoproteina;Cardiovasculardisease;Low-densitylipoproteincholesterol
尽管心血管疾病的防治取得了较为突出的成果,但其患病率和病死率仍较高。除了大家熟知的心血管疾病的危险因素外,脂蛋白a近年来引起了临床医务工作者的较高关注。脂蛋白a水平升高是心血管疾病发生的一个独立的致病危险因素,正在成为一个重要的临床靶点。降低血浆脂蛋白a水平的治疗措施也逐渐开展,是否能带来临床益处也逐渐得到解答。然而,关于脂蛋白a如何促进心血管疾病的发生发展以及如何更好地对其进行预防,是临床需要密切关注的。现就脂蛋白a的结构与作用机制、与心血管疾病的关系以及治疗的研究进展进行综述。
Although cardiovascular disease has achieved remarkable achievement, its incidence rate and mortality are still high. In addition to the well-known risk factors of cardiovascular disease, lipoprotein a [LP (a)] is a hot-button that sparked attention on clinical medical field in recent years. Elevated LP (a) is an independent risk factor for cardiovascular disease, and is becoming an important clinical target. The therapeutic measures to reduce the plasma Lp (a) level have been gradually carried out, and whether it can bring clinical benefits has been gradually answered. However, we need to pay close attention to how LP (a) can promote the occurrence and development of cardiovascular disease and how to better prevent it. In this review, the structure and mechanism of LP (a), the relationship between Lp (a) and cardiovascular disease, and the research progress of its treatment are reviewed.
copyright
地址:北京市朝阳区安贞路2号首都医科大学附属北京安贞医院北楼二层
电话:010-64456116 传真:010-64428528 邮编:100029 Email: zgyy8888@163.com
网址: 京ICP备2020043099号-3
当您在使用本网站投稿遇到困难时,请直接将稿件投送到编辑部邮箱zgyy8888@163.com。